

Metrobactin 250 mg tablets for cats and dogs

Authorised

- Metronidazole

Product identification

Medicine name:

Metrobactin 250 mg tablets for cats and dogs

Active substance:

Metronidazole

Target species:

Dog

Cat

Route of administration:

Oral use

Product details

Active substance and strength:

Metronidazole

250.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ01XD01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Norway

Package description:

Aluminium - PVC/PE/PVDC blister. Cardboard box of 9 blisters of 10 tablets
Aluminium - PVC/PE/PVDC blister. Cardboard box of 8 blisters of 10 tablets
Aluminium - PVC/PE/PVDC blister. Cardboard box of 6 blisters of 10 tablets
Aluminium - PVC/PE/PVDC blister. Cardboard box of 50 blisters of 10 tablets
Aluminium - PVC/PE/PVDC blister. Cardboard box of 7 blisters of 10 tablets
Aluminium - PVC/PE/PVDC blister. Cardboard box of 3 blisters of 10 tablets
Aluminium - PVC/PE/PVDC blister. Cardboard box of 25 blisters of 10 tablets
Aluminium - PVC/PE/PVDC blister. Cardboard box of 5 blisters of 10 tablets
Aluminium - PVC/PE/PVDC blister. Cardboard box of 4 blisters of 10 tablets
Aluminium - PVC/PE/PVDC blister. Cardboard box of 1 blister of 10 tablets.
Aluminium - PVC/PE/PVDC blister. Cardboard box containing 10 boxes, each containing 10 blisters of 10 tablets.
Aluminium - PVC/PE/PVDC blister. Cardboard box of 2 blisters of 10 tablets
Aluminium - PVC/PE/PVDC blister. Cardboard box of 10 blisters of 10 tablets
Aluminium - PVC/PE/PVDC blister. Cardboard box containing 10 boxes, each containing 1 blisters of 10 tablets.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Dechra Regulatory B.V.

Marketing authorisation date:

6/02/2017

Manufacturing sites for batch release:

Lelypharma B.V.

Genera d.d.

Responsible authority:

Norwegian Medical Products Agency

Authorisation number:

14-10401

Date of authorisation status change:

9/11/2021

Reference member state:

Netherlands

Procedure number:

NL/V/0193/001

Concerned member states:

Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland
France Germany Greece Hungary Iceland Ireland Italy Latvia Lithuania
Luxembourg Norway Poland Portugal Romania Slovakia Slovenia Spain
Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet